Telefonica Brasil S.A. (NYSE:VIV)
Telefonica Brasil S.A. (NYSE:VIV) represented a move of -1.74 percent or $0.18 per share and closed its previous day trading session at $11.85. 849561 Shares were traded in the last trading session with an Average Volume of 2.09 Million Shares. The stock currently has a Market Capitalization of 20.07 Billion.
Telefonica Brasil SA is engaged in providing communication, information and entertainment solutions in the telecommunication sector, in the State of Sao Paulo. The Company also provides multimedia communication services, local voice services, long-distance services, data services, Pay TV services, land-based wireless technology multichannel multipoint distribution service and network services. Telefonica Brasil SA was formerly known as Telecomunicacoes de Sao Paulo S.A.
The stock traded between $ 9.21 and $17.33 over 1-Year time period showing its price to sales ratio of 1.78. Telefonica Brasil S.A. (NYSE:VIV) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $9.14 and 200-Day Simple Moving Average of $0.15. Its Price to Free Cash Flow is 0 and Price to Book of 1.08.
Analyst’s recommended the stock as 2.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Telefonica Brasil S.A. (NYSE:VIV) reported its Actual EPS of $0.27/share. The analysts offering Earnings Estimates for the company were believing that Telefonica Brasil S.A. could bring EPS of $0.27/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
In the last trading session, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) added its value by -0.62% closing at the price of $14.52. The stock currently has market capitalization of 1.29 Billion, with average volume of 2.62 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is showing beta of 2.03. This particular value of beta suggests that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has historically moved 203% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is at $-0.68.
The stock currently has RSI of 52.26. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) topped its 52-week high price of $22.39 on 09/06/18 and 52-Week Low Price of $ 3.01 on 12/13/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.75% and monthly volatility of 7.72% respectively.